initiated a single center program in which pts with R/R aBCL were treated with locally produced anti-CD19 CAR T-cells. Eligibility of the pts enrolled reflected a real world setting. Aim: To evaluate the safety, efficacy, and clinical/PET-CT imaging parameters associated with survival outcomes. Methods: Pts with R/R aBCL and adequate organ function were eligi- ble. The approach used autologous T-cells expressing anti-CD19 CAR construct with CD28 co-stimulatory domain. Treatment included lymphodepletion with fludarabine and cyclophosphamide followed by infusion of fresh 1 X 10 6 CAR T-cells after 9-10 days of culture. Base- line PET-CT scans, which were done within maximum 2 weeks before CAR T-cell treatment, were analyzed for total lesion glycolysis (TLG) and total metabolic tumor volume, using a segmentation algorithm of 41%SUVmax (TMTV41%). Results: Between November 2016 and January 2019, 30 pts with R/R aBCL were included: 25 with diffuse large B cell lymphoma (6 of them were transformed), 3 with primary mediastinal lymphoma and 2 with Burkitt lymphoma. 23 pts were male. Median age was 45 (range 19-66). Median number of prior therapies was 3 (range 2-6). 27 pts (90%) were refractory to their last therapy. 13 (43%) had a prior stem cell transplantation (SCT) (11 – auto, 1 – allo, 1 – auto and allo). The overall response rate was 57% (27% CR). With a median follow-up of 5.1 month (1.2-26.5) median overall and progression free survival (PFS) were 20.7 and 3.7 months, respectively. The estimated PFS at 18 months for the entire cohort was 25%, and 44% among the 17 pts who had an objective response. 11 patients deceased, 9 of them due to disease progression and 2 from transplant related toxicity. No deaths were attributed to CAR T-cell therapy. Cytokine release syn- drome occurred in 22 pts (73%), but was severe in only one. 11 pts (37%) experienced neurotoxicity, in 6 (20%) it was grade 3 or 4. Toxic- ities related to CAR T-cell therapy did not predict survival outcomes. Median baseline TMTV and TLG were 76 (7-1357) and 717 (19-8460), respectively. None of these PET-CT measurements and other baseline patient and disease characteristics, including CRP and stage, predicted OS or PFS. AlloSCT was performed after CAR T- cell therapy in 13/30 patients (43%). Severe acute GVHD and sinusoi- dal obstruction syndrome were identified in 2/13 patients (15%), each. Conclusion: This prospective analysis of a single center cohort of mostly refractory aBCL pts treated with in-house produced anti- CD19 CAR T-cell therapy suggests that long-term responses may be achieved, particularly in pts who had an objective response. None of the clinical and PET-CT parameters that indicate tumor burden predicted long term survival. Keywords: non-Hodgkin lymphoma (NHL); positron emission tomog- raphy (PET); T-cells. 478 INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL U. Jaeger 1 | C. Tam 2 | P. Borchmann 3 | J. McGuirk 4 | H. Holte 5 | E. Waller 6 | S. Jaglowski 7 | C. Andreadis 8 | S.R. Foley 9 | I. Fleury 10 | J. Westin 11 | T. Teshima 12 | S. Mielke 13 | G. Salles 14 | P.J. Ho 15 | K. Izutsu 16 | S. Schuster 17 | V. Bachanova 18 | R. Maziarz 19 | K. Van Besien 20 | M.J. Kersten 21 | N. Wagner-Johnston 22 | K. Kato 23 | P. Corradini 24 | R. Tiwari 25 | A. Forcina 26 | L. Pacaud 27 | M. Bishop 28 1 Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 2 Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, Australia; 3 Department of Hematology/Oncology, University Hospital of Cologne, Cologne, Germany; 4 Division of Hematologic Malignancies and Cellular Therapeutics, Kansas Hospital and Medical Center, Kansas City, United States; 5 Lymphoma Section, University of Oslo, Oslo; 6 Hematology and Medical Oncology, Medicine and Pathology, Emory University School of Medicine, Atlanta, United States; 7 Department of Hematology, Ohio State University, Columbus; 8 Department of Hematology and Blood and Marrow Transplant, University of California San Francisco, San Francisco, United States; 9 Division of Clinical Pathology, McMaster University, Hamilton, Canada; 10 Department of Hematology, Hôpital Maisonneuve- Rosemont, Montreal, Canada; 11 Department of Lymphoma & Meyloma, MD Anderson Cancer Center, Houston, United States; 12 Department of Hematology, Hokkaido University Hospital, Sapporo, Japan; 13 Department of Internal Medicine, University Hospital Wuerzburg, Wuerzburg, Germany; 14 Department of Hematology/Oncology, Hospital Center Lyon-Sud, Pierre-Benite, France; 15 Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia; 16 Department of Hematology, National Cancer Center Hospital, Tokyo, Japan; 17 Division of Hematology Oncology, University of Pennsylvania, Philadelphia, United States; 18 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, United States; 19 Department of Hematology, Oregon Health and Science University, Portland, United States; 20 Department of Medical Oncology, Weill Cornell Medicine, New York, United States; 21 Department of Hematology, Academic Medical Center, Amsterdam, Netherlands; 22 Department of Hematology/Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States; 23 Department of Haematology, Kyushu University Hospital, Fukuoka Prefecture, Japan; 24 Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; 25 Global Medical Affaris, Novartis Pharmaceuticals Corporation, Hyderabad, India; 26 Novartis Oncology, Novartis Pharma AG, Basel, Switzerland; 27 Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, United States; 28 Section of Hematology/Oncology, University of Chicago, Chicago, United States Background: Tisagenlecleucel is an anti-CD19 chimeric antigen recep- tor (CAR)-T cell therapy that has demonstrated durable responses and ABSTRACT 505